explore -WSS

explore

author：entertainment 2025-10-01 17:20:13 - browse：6251

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Republican states more likely to report Covid vaccine side effects

WSS

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Gut bacteria may contribute to kidney autoimmunity, study finds

Bird flu reported in person exposed to presumably infected cattle

Bird flu reported in person exposed to presumably infected cattle

Scientific mystery highlights the blind spots in genomics databases

Hundreds died while taking an arthritis drug, but nobody alerted patients

Wikipedia

explore

leisure time

Activists slam private health insurers over coverage restrictions

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Moonlake's readout produced a cash windfall. Risks remain

Hundreds died while taking an arthritis drug, but nobody alerted patients

Activists slam private health insurers over coverage restrictions

Biotech companies concerned about China biosecurity crackdown

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Kenai launches with $82 million for Parkinson’s stem cell therapy

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

hotspot

Obesity now affects over 1 billion people worldwide, study finds

Why getting cancer drugs just got harder for rural patients

Medical device lobby: We're tired of waiting on Medicare coverage

RSV vaccines may be linked to small increased risk of developing GBS

Scientific mystery highlights the blind spots in genomics databases

Study: Black kids more likely to die after surgery than white kids

Wikipedia

entertainment

explore

hotspot